ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0043189 | null | Wing|Wing structure|wings|Wings|wing|Wing structure (body structure)|winged|winging | Wing |
C0769635 | Separase is a caspase-like cysteine protease, which plays a central role in triggering ANAPHASE by cleaving the SCC1/RAD21 subunit of the cohesin complex. Cohesin holds the sister CHROMATIDS together during METAPHASE and its cleavage results in chromosome segregation. | Separase | separase |
C0598175 | The process in which genetic material, in the form of chromosomes, is organized into specific structures and then physically separated and apportioned to two or more sets. In eukaryotes, chromosome segregation begins with the condensation of chromosomes, includes chromosome separation, and ends when chromosomes have completed movement to the spindle poles. [GOC:jl, GOC:mah, GOC:mtg_cell_cycle, GOC:vw] | Segregation, Chromosome|chromosome division|chromosome segregation|Chromosome Segregations|Chromosome Segregation|Segregations, Chromosome | Chromosome Segregation |
C1309232 | null | G protein-regulated inducer of neurite outgrowth, mouse|KIAA0514 protein, mouse | Gprin2 protein, mouse |
C1309232 | null | G protein-regulated inducer of neurite outgrowth, mouse|KIAA0514 protein, mouse | Gprin2 protein, mouse |
C1309232 | null | G protein-regulated inducer of neurite outgrowth, mouse|KIAA0514 protein, mouse | Gprin2 protein, mouse |
C1309232 | null | G protein-regulated inducer of neurite outgrowth, mouse|KIAA0514 protein, mouse | Gprin2 protein, mouse |
C0015161 | Cells of the higher organisms, containing a true nucleus bounded by a nuclear membrane. | Eukaryotic cells|Eukaryotic Cell|eukaryotic cells|Cell, Eukaryotic|eukaryote|eukaryotic cell|eukaryotida|Eukaryotic Cells|Cells, Eukaryotic | Eukaryotic Cells |
C1179106 | null | Motor protein|motor protein | Motor protein |
C0085139 | A microtubule-associated mechanical adenosine triphosphatase, that uses the energy of ATP hydrolysis to move organelles along microtubules toward the plus end of the microtubule. The protein is found in squid axoplasm, optic lobes, and in bovine brain. Bovine kinesin is a heterotetramer composed of two heavy (120 kDa) and two light (62 kDa) chains. | Kinesin|kinesin|kinesins | Kinesin |
C0041526 | null | U2 snRNA|U2 RNA | U2 small nuclear RNA |
C1179106 | null | Motor protein|motor protein | Motor protein |
C0230595 | Extra-nucleolar nuclear domains usually visualized by confocal microscopy and fluorescent antibodies to specific proteins. [GOC:ma, PMID:10330182] | bodies nuclear|nuclear body|Nuclear body|Intranuclear body, NOS|Intranuclear body (cell structure) | Intranuclear body |
C0814193 | null | Clinical Institute Withdrawal Assessment|ciwa|CIWA | clinical institute withdrawal assessment (CIWA) for alcohol |
C0814193 | null | Clinical Institute Withdrawal Assessment|ciwa|CIWA | clinical institute withdrawal assessment (CIWA) for alcohol |
C0019868 | The processes whereby the internal environment of an organism tends to remain balanced and stable. | Autoregulation|Homeostasis|Homeostasis, function|homeostasis- body function that maintain internal balance by adjusting its physiological processes.|Homeostasis, function (observable entity)|metabolic equilibrium|autoregulation|Physiological Homeostasis|Homoeostasis|homeostatic|Homeostatic Process|homeostasis|homeostatic process | Homeostasis |
C1159974 | The process whereby a relatively unspecialized cell acquires the specialized features of an osteoblast, a mesodermal or neural crest cell that gives rise to bone. [CL:0000062, GO_REF:0000034, GOC:jid] | osteoblast cell differentiation | osteoblast differentiation |
C0005495 | The process by which life began. | Life Geneses|Life Genesis|Life Origins|Origin of Life|Life Origin|Life--Origin|biogenesis|biogeneses|origin of life|Genesis of Life | Origin of Life |
C0240016 | null | insulin uses|use insulin|Insulin used (attribute)|INSULIN USE|insulin use | Insulin used |
C1326961 | Any process involved in the maintenance of an internal steady state of glucose within an organism or cell. [GOC:go_curators] | homeostasis glucose|glucose homeostasis | glucose homeostasis |
C1280188 | null | Entire jugular vein|Entire jugular vein (body structure) | Entire jugular vein |
C0012641 | null | disease clustering|clusters disease|Clusterings, Disease|Clustering, Disease|Disease Clusterings|disease cluster | Disease Clustering |
C0012641 | null | disease clustering|clusters disease|Clusterings, Disease|Clustering, Disease|Disease Clusterings|disease cluster | Disease Clustering |
C0175721 | A device designed to hold things firmly together. | CLAMP|clamp [device]|Clamp, device|Clamp, NOS|Clamp|Clamp Device|clamp|clamps|Clamp, device (physical object) | Clamp (device) |
C0936236 | null | Corticospinal Tract|corticospinal tract|Corticospinal tract, NOS|Tracts, Corticospinal|Tract, Corticospinal|Corticospinal Tracts|Corticospinal tract|corticospinal tracts | Corticospinal Tracts |
C0036113 | A serotype of Salmonella enterica which is an etiologic agent of gastroenteritis in man and other animals. | Salmonella enterica serovar enteritidis|Salmonella enterica subsp. enterica ser. Enteritidis|Salmonella Serotype Enteritidis|s. enteritidis|Salmonella enterica subsp. enterica serovar Enteritidis|salmonella enteritidis|Salmonella Enteritidis|Salmonella enterica subsp. enterica Serovar enteritidis|enteritidis salmonella|Salmonella 1,9,12:[f],g,m,[p]:[1,7]|Salmonella enteritidis|Salmonella Enteritidis (organism)|S. enteritidis|SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR ENTERITIDIS|Salmonella enterica subsp. enterica serovar enteritidis|Bacillus enteritidis|Salmonella 1,9,12:g,m:-|SALMONELLA SEROTYPE ENTERITIDIS|salmonella enterica subsp. enterica serovar enteritidis|SALMONELLA ENTERICA ENTERICA SEROVAR ENTERITIDIS | Salmonella enterica subsp. enterica serovar enteritidis |
C0376613 | Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers. | Naked DNA Vaccines|DNA Vaccines|Recombinant DNA Vaccines|dna vaccines|DNA Vaccine|vaccine dna|DNA vaccines|Vaccines, Naked DNA|DNA vaccine|Vaccines, Recombinant DNA|dna vaccine|DNA Vaccines, Naked|DNA Vaccines, Recombinant | Vaccines, DNA |
C0002371 | A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc. | hydrated alumina|Aluminium hydroxide-containing product|ALUMINUM (AS HYDROXIDE)|Alumina, Hydrated|aluminum hydroxide antacid|alum adjuvant|Aluminum hydroxide-containing product|Hydrated Alumina|Algeldrate|aluminum hydroxide|Aluminium hydroxide (substance)|aluminium hydroxide|Aluminium hydroxide|ALUMINUM HYDROXIDE|Aluminum Hydroxide|Alum Adjuvant|alumina hydrate|Aluminum hydroxide (Al(OH)3)|Hydroxide, Aluminum|Aluminio hidróxido|Product containing aluminium hydroxide (medicinal product)|Aluminum hydroxide | aluminum hydroxide |
C0006560 | A plasma protein that circulates in increased amounts during inflammation and after tissue damage. | Protein, C-Reactive|c reactive protein|CRP|C reactive protein (substance)|C Reactive Protein|CRP - C-reactive protein|c reactive proteins|Proteins, specific or class, C-reactive|c-reactive protein (CRP)|C-reactive protein|C reactive protein|C-Reactive Protein | C-reactive protein |
C0042971 | A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor. | Ristocetin Cofactor|Ristocetin-Willebrand Factor|von Willebrand factor ristocetin cofactor|Factor VIII-associated antigen|factor von willebrands|von Willebrand factor|Factor VIIIR Ag|ristocetin cofactor|von Willebrand factor antigen|vWFAg - von Willebrand factor antigen|VWF|Factor VIIIR RCo|Factor VIII-related antigen|von Willebrand factor (substance)|Factor von Willebrand|von Willebrand factor-containing product|Factor VIII Related Antigen|VON WILLEBRAND FACTOR|von willebrand factor antigen|Factor VIIIR-RCo|factor von willebrand|von Willebrand Factor|vwf|Product containing von Willebrand factor (medicinal product)|Von Willebrand factor|vWF- von Willebrand factor|von willebrand factor|Factor VIIIR-Ag|von willebrand factor ag|RAg - Factor VIII-related antigen|von Willebrand factor antigen (substance)|Factor VIII-Related Antigen|Ristocetin Willebrand Factor|von Willebrand Protein | von Willebrand factor |
C0030190 | A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators. | Protein, SERPINE1|Serpin E1|pai 1|Plasminogen activator inhibitor-1 (substance)|Type 1 Plasminogen Activator Inhibitor|Plasminogen activator inhibitor-1|SERPINE1 Protein|pai-1|PAI-1|Plasminogen Activator Inhibitor 1|E1, Serpin | Plasminogen Activator Inhibitor 1 |
C0021740 | A recombinant therapeutic agent which is chemically identical to or similar to the endogenous lymphokine interferon gamma (IFN-gamma) with antineoplastic, immunoregulatory, and antiviral activities. Therapeutic IFN-gamma binds to and activates the cell-surface IFN-gamma receptor, stimulating antibody-dependent cytotoxicity and enhances natural killer cell attachment to tumor cells. This agent also activates caspases, thereby inducing apoptosis in malignant cells. (NCI04) | Interferon Gamma (BIO)|Interferon Gamma|Recombinant Interferon Gamma|Gamma-Interferon|recombinant interferon gamma|Gamma Interferon (GEN)|IFN-g|Interferon, Gamma|Ginterferon|Gamma Interferon-SCH | Recombinant Interferon-gamma |
C0021758 | A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells. | IgE/IgG1 enhancing factor|B cell growth factor|BCSF 1|Mast cell growth factor 2|BAF (B cell activating factor)|B Cell Growth Factor I|B-Cell Proliferating Factor|interleukin-4 (IL-4)|MCGF-2|il-4|BCGF-1|Interleukin 4|B-cell activating factor|B Cell Stimulatory Factor 1|T-cell growth factor 2|B Cell Proliferating Factor|Interleukin-4 (substance)|B Cell Stimulatory Factor-1|Mast Cell Growth Factor 2|TCGF 2|Interleukin-4|B-Cell Stimulatory Factor-1|BCAF|B-Cell Growth Factor-1|B Cell Growth Factor 1|B-cell growth factor|interleukin-4|Mast Cell Growth Factor-2|BCGF (B cell growth factor)|BCGF|MCGF 2|interleukin 4|B cell stimulating factor 1|B-Cell Stimulating Factor-1|B cell activating factor|IL4|BSF1|BSF-1|IL-4|B-cell stimulating factor|B-Cell Stimulatory Factor 1|b cell growth factor|BSF1 (B cell stimulating factor 1)|B Cell Stimulating Factor 1|B-Cell Growth Factor-I | interleukin-4 |
C0005778 | The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. | Clotting|Coagulation, Blood|Blood Clottings|Blood coagulation|Blood Clotting|Coagulation Process|Clotting, Blood|Coagulation|blood coagulations|Blood--Coagulation|blood clotting|Blood clotting|Blood Coagulation|blood coagulation|Coagulation-Related Process | Blood coagulation |
C0013884 | Parasitic infestation of the human lymphatic system by WUCHERERIA BANCROFTI or BRUGIA MALAYI. It is also called lymphatic filariasis. | Elephantiasis, Filarial|Lymphatic Filariases|Filarial Elephantiasis|Filarial elephantiasis|Lymphatic filariasis|Filarial Elephantiases|Filariasis, Lymphatic|lymphatic filariasis|ELEPHANTIASIS, FILARIAL|filariasis lymphatic|Lymphatic filariasis (disorder)|Elephantiases, Filarial|Filariases, Lymphatic|Lymphatic Filariasis|Elephantiasis | Filarial Elephantiases |
C0747256 | A successful invasion of a host by an organism that uses the host for food and shelter. | Parasitic Infection|Parasitic infectious disease|Parasitic infection, NOS|Parasitic infection|Parasitic Disease|INFECTION PARASITIC|Parasitic infectious disease, NOS | Parasitic infection |
C1444132 | null | Immunochromatographic test (procedure) | Immunochromatographic test |
C0022727 | A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria whose organisms arrange singly, in pairs, or short chains. This genus is commonly found in the intestinal tract and is an opportunistic pathogen that can give rise to bacteremia, pneumonia, urinary tract and several other types of human infection. | klebsiella|Genus Klebsiella|Hyalococcus|Klebsiella|Klebsiella species|KLEBSIELLA|Klebsiella, NOS|Donovania|Calymmatobacterium|Genus Klebsiella (organism) | Klebsiella |
C0877445 | A form of invasive candidiasis where species of CANDIDA are present in the blood. | Candidemia (disorder)|candidaemia|Candidemia|candidemia | Candidemia |
C0016277 | Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS. | FCZ|Fluconazole|Product containing fluconazole (medicinal product)|Fluconazolum|Difluconazole|fluconazole|alpha-(2,4-difluorophenyl)-alpha- (1,2,4-triazol-1-ylmethyl)-1,2, 4- triazole-1-ethanol|Fluconazole (substance)|Fluconazole-containing product|1H-1,2,4-Triazole-1-ethanol, alpha-(2,4-difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-|Fluconazol|FLUCONAZOLE | fluconazole |
C0085468 | A species of aerobic, Gram negative, rod shaped, bacteria assigned to the phylum Proteobacteria. This species is oxidase positive, nonmotile, and requires serum or blood for growth in culture. M. bovis is pathogenic, being the causative agent of infectious bovine keratoconjunctivitis. However only the piliated variant can colonize the conjunctiva. | Moraxella bovis|Moraxella bovis (organism)|MORAXELLA BOVIS|Haemophilus bovis|Hemophilus bovis|Moraxella duplex des bovids|Moraxella (Moraxella) bovis | Moraxella bovis |
C0031669 | An enzyme found in the alpha-toxin of Clostridium welchii and other strains of clostridia and bacilli. It hydrolyzes glycerophosphatidates with the formation of 1,2-diacylglycerol and a phosphorylated nitrogenous base such as choline. | lipophosphodiesterase I|phospholipase c|phosphatidylcholine cholinephosphohydrolase|Phospholipase C (substance)|alpha-toxin|Phospholipase C|phospholipase C|alpha toxin|lecithinase C|Clostridium oedematens beta- and gamma-toxins|PLC|Lecithinase C|Lipophosphodiesterase I|Clostridium welchii alpha-toxin | Phospholipase C |
C0026917 | The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. | Bovine tubercle bacillus|Tubercle bacillus, bovine|Mycobacterium bovis|Mycobacterium bovis (organism)|MYCOBACTERIUM BOVIS|mycobacterium bovis | Mycobacterium bovis |
C1032649 | A group of four closely related tuberculosis-causing bacteria: M. bovis, M. africanum, M. canetti and M. microti. | MYCOBACTERIUM TUBERCULOSIS COMPLEX|Mycobacterium complex|Mycobacterium tuberculosis complex (organism)|Mycobacterium tuberculosis Complex|Mycobacterium tuberculosis group|Mycobacterium tuberculosis complex | Mycobacterium tuberculosis complex |
C0031669 | An enzyme found in the alpha-toxin of Clostridium welchii and other strains of clostridia and bacilli. It hydrolyzes glycerophosphatidates with the formation of 1,2-diacylglycerol and a phosphorylated nitrogenous base such as choline. | lipophosphodiesterase I|phospholipase c|phosphatidylcholine cholinephosphohydrolase|Phospholipase C (substance)|alpha-toxin|Phospholipase C|phospholipase C|alpha toxin|lecithinase C|Clostridium oedematens beta- and gamma-toxins|PLC|Lecithinase C|Lipophosphodiesterase I|Clostridium welchii alpha-toxin | Phospholipase C |
C0162801 | A multistage process that includes the determination of a sequence (protein, carbohydrate, etc.), its fragmentation and analysis, and the interpretation of the resulting sequence information. | Sequence Analysis|Sequencing|Analyses, Sequence|Analysis, Sequence|Sequence Analyses | Sequence Analysis |
C0599927 | null | null | southern hybridization |
C0377800 | null | protein b|b protein | protein B |
C0026926 | A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. | TB bacillus|Bacillus tuberculosis|MYCOBACTERIUM TUBERCULOSIS|bacterium tuberculosis|Mycobacterium tuberculosis (organism)|tb bacillus|tuberculosis bacillus|Koch's bacillus|M. tuberculosis|m tuberculosis|MTB - Mycobacterium tuberculosis|Human tubercle bacillus|Mycobacterium tuberculosis variant tuberculosis|mycobacterium tuberculosis|Mycobacterium tuberculosis|Mycobacterium tuberculosis typus humanus|Tubercle bacillus, human|Mycobacterium tuberculosis hominis|mtb|tuberculosis mycobacterium|Mycobacterium tuberculosis hominis (organism)|Bacterium tuberculosis|m. tuberculosis|Mycobacterium tuberculosis var. hominis | Mycobacterium tuberculosis |
C0023922 | A protein, molecular weight 50 kD, located in various normal tissues. Upon cleavage by KALLIKREINS, it forms KALLIDIN. Kallidin, in turn, is converted into BRADYKININ. (From Stedman, 25th ed) | LMWK|Low molecular weight kininogen (substance)|Low-Molecular-Weight Kininogens|Low Molecular Weight Kininogen|Kininogen, Low-Molecular-Weight|Low molecular weight kininogen|Kininogen, Low Molecular Weight|Kininogens, Low-Molecular-Weight|Low-Molecular-Weight Kininogen|Low Molecular Weight Kininogens | Kininogen, Low-Molecular-Weight protein |
C0023922 | A protein, molecular weight 50 kD, located in various normal tissues. Upon cleavage by KALLIKREINS, it forms KALLIDIN. Kallidin, in turn, is converted into BRADYKININ. (From Stedman, 25th ed) | LMWK|Low molecular weight kininogen (substance)|Low-Molecular-Weight Kininogens|Low Molecular Weight Kininogen|Kininogen, Low-Molecular-Weight|Low molecular weight kininogen|Kininogen, Low Molecular Weight|Kininogens, Low-Molecular-Weight|Low-Molecular-Weight Kininogen|Low Molecular Weight Kininogens | Kininogen, Low-Molecular-Weight protein |
C0948008 | An acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of brain tissue. | stroke ischemic|ischaemic strokes|STROKE, ISCHEMIC|ischaemic stroke|Stroke, ischemic|ischemic strokes|Ischemic Cerebrovascular Accident|Ischemic stroke (disorder)|ISCHEMIC STROKE|Ischaemic stroke|Ischemic stroke|ischemic stroke|Arterial Ischemic Stroke|Ischemic Stroke | Ischemic stroke |
C0270611 | Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits. | brain damages|Brain tissue injury|Cerebral damage|Brain damage, NOS|Damage, brain|brain disorders injury|brain tissue injury|Injury, Brain|Brain Injuries|Intracerebral injury|brain injury|cerebral damage|Brain damage|damage brain|brain injury tissue|injury brain|brain lesion (from injury)|disorder brain injury|Injuries, Brain|Brain Injury|Acquired brain injury|brain damage|brain injuries|Brain Damage|cerebral injury | Brain Injuries |
C1174751 | null | Certican | Certican |
C0729936 | Organ chamber which consists of a wall that surrounds the cavity of a cardiac atrium or ventricle. | cardiac chamber|Cardiac chamber|Cardiac chamber structure|Endocardiac|cardiac chambers|Cardiac chamber, NOS|heart chamber|Chamber of heart|heart chambers|chamber of heart|Intracardiac|Cardiac chamber structure (body structure)|Intracardiac (qualifier value) | Cardiac chamber structure |
C0085826 | An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system. | antiplatelet agent|antiplatelet drug|Agents, Antiplatelet|antiplatelets drugs|Antiplatelet Drugs|Drugs, Antiplatelet|Antiplatelet agent|Antiplatelet Agent|antiplatelet drugs|drugs antiplatelet|Medicinal product acting as antiplatelet agent (product)|antiplatelet agents|Antiplatelet agent (substance) | Antiplatelet Agents |
C0456909 | The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE. | BLINDNESS|Blind|VISION LOSS|Blindness, NOS|Total vision loss|blind|blind vision|Visual loss, NOS|Blindness|blindness | Blindness |
C0432252 | An autosomal recessive condition caused by homozygous or compound heterozygous inactivating mutation(s) in the gene LRP5, encoding low-density lipoprotein receptor-related protein 5. This condition is characterized by severe juvenile-onset osteoporosis and congenital or juvenile-onset blindness due to a vascularized retinal mass that resembles a glioma. | Osteoporosis with pseudoglioma (disorder)|OSTEOGENESIS IMPERFECTA, OCULAR FORM|osteoporosis pseudoglioma|OPS|osteoporosis with pseudoglioma|Osteoporosis-pseudoglioma syndrome|Osteoporosis with pseudoglioma|Pseudoglioma with bone fragility|Osteogenesis imperfecta, ocular form|Osteoporosis Pseudoglioma Syndrome|OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME|OPPG | Osteoporosis with pseudoglioma |
C0751815 | The splitting of the vessel wall in one or both (left and right) internal carotid arteries (CAROTID ARTERY, INTERNAL). Interstitial hemorrhage into the media of the vessel wall can lead to occlusion of the internal carotid artery and aneurysm formation. | Dissection of internal carotid artery (disorder)|Dissection, Internal Carotid Artery|Internal carotid artery dissection|Dissection of internal carotid artery|Internal Carotid Artery Dissection|Carotid Artery Dissection, Internal | Carotid Artery, Internal, Dissection |
C0086130 | N,alpha-dimethyl-N,2- propynyl phenethylamine, a MAO inhibitor which blocks the conversion of MPTP to MPP+ in animal models of Parkinson's disease, and may therefore have therapeutic potential. | deprenyl | Deprenyl |
C1281954 | null | Entire right frontal lobe (body structure)|Entire right frontal lobe | Entire right frontal lobe |
C0027832 | An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life. | NF2s (Neurofibromatosis 2)|Type II Neurofibromatoses|Neurofibromatosis, central type|Neurofibromatoses, Type 2|Acoustic Neurofibromatosis, Bilateral|Central Neurofibromatoses|Neurofibromatosis, Bilateral Acoustic|Neurofibromatoses, Bilateral Acoustic|Type 2 Neurofibromatoses|Acoustic Neurofibromatosis|Neurofibromatosis 2|Neurofibromatosis, Central, NF2|Type 2 Neurofibromatosis|Neurofibromatoses, Central NF2|Neurofibromatosis, type 2|Bilateral acoustic neurofibromatosis|Familial vestibular schwannoma|acoustic neurofibromatosis|NF2|Central NF2 Neurofibromatoses|Central NF2 Neurofibromatosis|NF2 (Neurofibromatosis 2)|Neurofibromatosis, Type II|Neurofibromatosis type 2 (disorder)|Neurofibromatosis type 2|Neurofibromatosis II|Bilateral Acoustic Neurofibromatoses|Neurofibromatosis, type 2 [acoustic neurofibromatosis]|Type II Neurofibromatosis|BANF|Neurofibromatoses, Type II|Acoustic Neurofibromatoses, Bilateral|Acoustic neurofibromatosis|Familial acoustic neuroma|Central Neurofibromatosis|Neurofibromatosis, Central, NF 2|neurofibromatosis type ii|Neurofibromatosis, Type 2|BILATERAL ACOUSTIC NEUROFIBROMATOSIS|Neurofibromatosis Type II|neurofibromatosis 2|Neurofibromatoses, Central|neurofibromatosis type 2|Neurofibromatosis IIs|Neurofibromatosis, Central NF2|Neurofibromatosis, Central|BANF - Bilateral acoustic neurofibromatosis|type 2 neurofibromatosis|neurofibromatosis ii|Neurofibromatosis Type 2|Bilateral Acoustic Neurofibromatosis|Neurofibromatosis, Acoustic, Bilateral|NEUROFIBROMATOSIS, TYPE II|NEUROFIBROMATOSIS, CENTRAL TYPE | Neurofibromatosis 2 |
C0115471 | An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. | 3,4-Methylenedioxymethamphetamine|3,4 methylenedioxymethamphetamine|n-Methyl-3, 4-methylenedioxyamphetamine|N Methyl 3,4 methylenedioxyamphetamine|Methylene-dioxymethamphetamine|MDMA - methylenedioxymethamphetamine|mdm|ecstasy (drug)|Ecstasy|MIDOMAFETAMINE|methylenedioxymethamphetamine|1,3-Benzodioxole-5-ethanamine, N,alpha-dimethyl-|Ecstasy (Drug)|Methylenedioxymethamfetamine|3,4-methylenedioxymethamphetamine|Midomafetamine|mdma|MDM|ecstasy|MDMA|N-Methyl-3,4-methylenedioxyamphetamine|methylene dioxymethamphetamine|XTC|Methylenedioxymethamphetamine (substance)|Methylenedioxymethamphetamine|ecstasy drug | Midomafetamine |
C0152025 | Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance. | polyneuropathies|POLYNEUROPATHY|Polyneuropathy, NOS|Polyneuropathy (disorder)|Polyneuropathy|Polyneuropathies|polyneuropathy|Polyneuropathy (multiple nerve disorder) | Polyneuropathy |
C0007959 | A hereditary motor and sensory neuropathy transmitted most often as an autosomal dominant trait and characterized by progressive distal wasting and loss of reflexes in the muscles of the legs (and occasionally involving the arms). Onset is usually in the second to fourth decade of life. This condition has been divided into two subtypes, hereditary motor and sensory neuropathy (HMSN) types I and II. HMSN I is associated with abnormal nerve conduction velocities and nerve hypertrophy, features not seen in HMSN II. (Adams et al., Principles of Neurology, 6th ed, p1343) | Charcot-Marie Disease|Peroneal muscular atrophy|Charcot-Marie-Tooth Disease|Peroneal Muscular Atrophies|CHARCOT-MARIE-TOOTH|CHARCOT-MARIE-TOOTH ATROPHY|Atrophies, Peroneal Muscular|charcot marie tooth syndrome|Atrophy, Muscular, Peroneal|Muscular Atrophy, Peroneal|Charcot-Marie-Tooth Syndrome|charcot-marie-tooth syndrome|Syndrome, Charcot-Marie-Tooth|Charcot-Marie-Tooth Hereditary Neuropathy|Atrophy, Peroneal Muscular|Charcot Marie Tooth Disease|Charcot Marie Tooth Hereditary Neuropathy|charcot-marie-tooth disease|Peroneal Muscular Atrophy|Charcot Marie Tooth Syndrome|Charcot Marie Disease|charcot marie tooth disease|peroneal muscular atrophy|Hereditary Neuropathy, Charcot-Marie-Tooth|Charcot Marie Tooth muscular atrophy|Peroneal muscular atrophy syndrome|Charcot-Marie-Tooth disease|Charcot-Marie-Tooth syndrome|Muscular Atrophies, Peroneal|PERONEAL MUSCULAR ATROPHY|Charcot Marie Tooth disease | Charcot-Marie-Tooth Disease |
C0282587 | Cell adhesion molecule involved in a diverse range of contact-mediated interactions among neurons, astrocytes, oligodendrocytes, and myotubes. It is widely but transiently expressed in many tissues early in embryogenesis. Four main isoforms exist, including CD56; (CD56 ANTIGEN); but there are many other variants resulting from alternative splicing and post-translational modifications. (From Pigott & Power, The Adhesion Molecule FactsBook, 1993, pp115-119) | neural cell adhesion molecules|ncam|neural cell adhesion molecule (NCAM)|neural cell adhesion molecule|Cell Adhesion Molecule, Neural|Neural Cell Adhesion Molecule|Neural cell adhesion molecule|Neural Cell Adhesion Molecules|N-CAM - neural cell adhesion molecule|NCAM|N-CAM|Cell Adhesion Molecules, Neural | Neural Cell Adhesion Molecules |
C0018946 | Accumulation of blood in the SUBDURAL SPACE between the DURA MATER and the arachnoidal layer of the MENINGES. This condition primarily occurs over the surface of a CEREBRAL HEMISPHERE, but may develop in the spinal canal (HEMATOMA, SUBDURAL, SPINAL). Subdural hematoma can be classified as the acute or the chronic form, with immediate or delayed symptom onset, respectively. Symptoms may include loss of consciousness, severe HEADACHE, and deteriorating mental status. | Subdural haematoma|SDH - Subdural haematoma|Subdural intracranial hemorrhage (disorder)|Subdural intracranial haemorrhage|SUBDURAL HEMATOMA|subdural haemorrhage|Subdural hemorrhage|Hematoma, Subdural|subdural hemorrhage|Subdural hematoma|Subdural haematoma, NOS|Subdural Hemorrhage|HEMATOMA SUBDURAL|SUBDURAL HEMATONIA|Subdural Hematoma|Subdural hemorrhage, NOS|subdural hemorrhages|Hematomas, Subdural|Subdural intracranial hemorrhage|subdural hematoma|SDH - Subdural hematoma|sdh|subdural haematoma|subdural hematoma (SDH)|Subdural hematoma, NOS|Subdural intracranial hematoma (disorder)|Subdural haemorrhage|subdural hematomas|Subdural intracranial haematoma|Subdural Hemorrhages|Hemorrhage, Subdural|HEMORRHAGE SUBDURAL|Subdural intracranial hematoma|Hemorrhages, Subdural|subdural bleeding|Subdural haemorrhage, NOS|Subdural Hematomas | Hematoma, Subdural |
C0027066 | Involuntary shock-like contractions, irregular in rhythm and amplitude, followed by relaxation, of a muscle or a group of muscles. This condition may be a feature of some CENTRAL NERVOUS SYSTEM DISEASES; (e.g., EPILEPSY, MYOCLONIC). Nocturnal myoclonus is the principal feature of the NOCTURNAL MYOCLONUS SYNDROME. (From Adams et al., Principles of Neurology, 6th ed, pp102-3). | Myoclonus|myoclonic jerking|MYOCLONUS|Myoclonic Jerks|Jerk, Myoclonic|myoclonic disorder|myoclonic jerks|Jerking, Myoclonic|Myoclonic Jerk|myoclonus|Myoclonic jerks|Myoclonic Jerking|Jerks, Myoclonic|involuntary muscle jerking|Myoclonus (finding)|Myoclonia|myoclonic jerk | Myoclonus |
C0840414 | null | Cervical spinal cord injury (disorder)|cervical cord injuries spinal|Cervical Spinal Cord Injury|spinal cord injury cervical|cervical spinal cord injury | Cervical spinal cord injury |
C0037929 | Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.). | spinal cord injury|Traumatic Myelopathy|Cord Trauma, Spinal|Spinal cord injury, NOS|Traumas, Spinal Cord|spinal cord injuries|Injuries, Spinal Cord|Spinal Cord Trauma|Trauma, Spinal Cord|Spinal cord injury|SCI - Spinal cord injury|Cord Injury, Spinal|Spinal Cord Injury|Myelopathies, Traumatic|Spinal Cord Traumas|Myelopathy, Traumatic|spinal cord trauma|Spinal Cord Injuries|Traumatic Myelopathies|Spinal cord injury (disorder)|Spinal cord syndrome|Injury, Spinal Cord|Cord Traumas, Spinal|Cord Injuries, Spinal | Spinal Cord Injuries |
C0032143 | A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. | Tissue Activator D-44|alteplase|Tissue plasminogen activator-containing product|TPA|Tissue Plasminogen Activator|Plasminogen Activator, Tissue Type|t-PA|TTPA|Alteplase (genetical recombination)|Alteplase-containing product|t-pa|Tissue Type Plasminogen Activator|Activase|Tissue-type plasminogen activator preparation|rt-PA|t-plasminogen activator|Product containing alteplase (medicinal product)|Recombinant Tissue Plasminogen Activator|Plasminogen activator (human tissue-type protein moiety)|T Plasminogen Activator|Tissue plasminogen activator alteplase|Plasminogen Activator, Tissue|Tissue plasminogen activator|T-PA|Alteplase|t-PA preparation|tPA|tpa|Product containing tissue plasminogen activator (medicinal product)|r-tPA|tissue plasminogen activator|Alteplase,recombinant|Plasminogen Activator, Tissue-Type|T-Plasminogen Activator|Tissue-Type Plasminogen Activator|Tissue plasminogen activator (substance)|Tisokinase|Tissue-type plasminogen activator|Alteplase (substance)|Alteplasa|TPA (tissue plasminogen activator)|ALTEPLASE,RECOMBINANT|rt-PA - Tissue-type plasminogen activator|recombinant tissue plasminogen activator|rt-PA preparation|ALTEPLASE|Plasminogen Activator (Human Tissue-Type Protein Moiety)|Tissue Activator D 44|Tissue plasminogen activator, recombinant|Alteplase, recombinant | alteplase |
C0751956 | null | Acute stroke|stroke acute|Acute Cerebrovascular Accident|Acute Cerebrovascular Accidents|Acute cerebrovascular accident (disorder)|Acute cerebrovascular accident|Acute Stroke|Stroke, Acute|Cerebrovascular Accident, Acute|acute cva|acute stroke|Acute Strokes|Cerebrovascular Accidents, Acute|Strokes, Acute | Acute Cerebrovascular Accidents |
C0016018 | Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. | Medicinal product acting as thrombolytic (product)|THROMBOLYTICS|Thrombolytic agent (substance)|Thrombolytic Agents|Fibrinolytic Drugs|Thrombolytic agent|thrombolytic drugs|fibrinolytic drugs|Antithrombotic Agent|Thrombolytic Drugs|fibrinolytic agent|Fibrinolytic agents|thrombolytics|thrombolytic drug|Fibrinolytic agent, NOS|Thrombolytic agent, NOS|THROMBOLYTIC AGENTS|Thrombolytic Agent|thrombolytic agent|thrombolytic|thrombolytic agents|Fibrinolytic Agents|fibrinolytic agents | Fibrinolytic Agents |
C0245561 | A drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in the hands or feet) that can occur with diabetes. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Cymbalta increases the amount of certain chemicals in the brain that help relieve depression and pain. It is a type of serotonin and norepinephrine reuptake inhibitor. | Duloxetine-containing product|Duloxetine (substance)|DULOXETINE|Duloxetine|Duloxetina|duloxetine|N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide|DULoxetine|N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine|Product containing duloxetine (medicinal product) | duloxetine |
C0178601 | Drugs that bind to and activate dopamine receptors. | Dopaminergic Agonists|Dopamine receptor agonist-containing product|Dopamine Agonists|Dopamine Receptor Agonist|Product containing dopamine receptor agonist (product)|Dopamine--Agonists|dopaminergic agonists|Agonist, Dopaminergic|Substance with dopamine receptor agonist mechanism of action|dopamine agonists|Dopaminergic Agonist|Agonist, Dopamine Receptor|Agonist, Dopamine|Substance with dopamine receptor agonist mechanism of action (substance)|dopamine agonist|Dopamine Receptor Agonists|dopamine receptor agonist|Dopamine agonists|Dopaminergics|Receptor Agonists, Dopamine|Agonists, Dopamine|Agonists, Dopamine Receptor|agonists dopamine receptor|Dopamine Agonist|Receptor Agonist, Dopamine|agonist dopamine receptor|Agonists, Dopaminergic|Dopamine receptor agonist | Dopamine Agonists |
C0023182 | The loss of cerebrospinal fluid into the surrounding tissues. | Fluid, Leakage Of Cerebrospinal|Leakage Of Cerebrospinal Fluid|CSF - Cerebrospinal fluid leak|Leak, Cerebrospinal Fluid|cerebrospinal fluid leak|Fluid Leakage, Cerebrospinal|Cerebrospinal Fluid Leakage|Fluid Drainage, Cerebrospinal|Cerebrospinal Fluid Leaks|csf leakage|Cerebrospinal fluid leakage (morphologic abnormality)|Drainages, Cerebrospinal Fluid|Leakage, Cerebrospinal Fluid|Cerebrospinal Fluid Leak|Cerebrospinal Fluid Drainages|Fluid Leaks, Cerebrospinal|Fluid Drainages, Cerebrospinal|Leaks, Cerebrospinal Fluid|Fluid Leak, Cerebrospinal|Drainage, Cerebrospinal Fluid|cerebrospinal fluid leakage|Cerebrospinal fluid leak (disorder)|Cerebrospinal Fluid Drainage|Spinal Cerebrospinal Fluid Leak|Cerebrospinal fluid leak|cerebrospinal fluid leaks|Cerebrospinal fluid leakage|leakage cerebrospinal fluid|Fluid Leakages, Cerebrospinal|Leakages, Cerebrospinal Fluid|Leakage, cerebrospinal fluid|Cerebrospinal Fluid Leakages | Cerebrospinal fluid leak |
C0016004 | An autologous or commercial tissue adhesive containing FIBRINOGEN and THROMBIN. The commercial product is a two component system from human plasma that contains more than fibrinogen and thrombin. The first component contains highly concentrated fibrinogen, FACTOR VIII, fibronectin, and traces of other plasma proteins. The second component contains thrombin, calcium chloride, and antifibrinolytic agents such as APROTININ. Mixing of the two components promotes BLOOD CLOTTING and the formation and cross-linking of fibrin. The tissue adhesive is used for tissue sealing, HEMOSTASIS, and WOUND HEALING. | Sealant, Fibrin|Adhesive, Fibrinogen|fibrin sealant|fibrin adhesive|fibrin sealants|Fibrin Sealant|Adhesive, Fibrin Tissue|Tissue Adhesive, Fibrin|Glue, Fibrin|Sealant System, Fibrin|Adhesive, Fibrin|fibrin glue|Fibrin tissue adhesive|Fibrin Adhesive|Fibrin Glue|FIBRIN SEALANT|Fibrinogen Adhesive|Autologous Fibrin Tissue Adhesive|Fibrin Sealant System | Fibrin Tissue Adhesive |
C0162702 | Surgical creation of a communication between a cerebral ventricle and the peritoneum by means of a plastic tube to permit drainage of cerebrospinal fluid for relief of hydrocephalus. (From Dorland, 28th ed) | Ventriculoperitoneostomy|Ventriculoperitoneal Shunts|Ventriculoperitoneal Shunt|Shunts, Ventriculo-peritoneal|Ventriculoperitoneal shunt (procedure)|shunting ventriculoperitoneal|Shunt, Ventriculoperitoneal|Creation of ventriculo-peritoneal shunt|Shunts, Ventriculoperitoneal|ventriculo-peritoneal shunt|Creation of VP shunt|ventriculo peritoneal shunt|shunt ventriculoperitoneal|Ventriculo peritoneal Shunt|ventriculoperitoneal shunt|Ventriculo-peritoneal Shunt|Insertion ventriculoperitoneal shunt|Shunt, Ventriculo-peritoneal|ventriculoperitoneal shunts|Ventriculo-peritoneal Shunts|Ventriculoperitoneal shunt | Creation of ventriculo-peritoneal shunt |
C1167250 | Any of the small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions. [PMID:16645198, PMID:20044567] | lipid rafts|lipid raft|membrane raft | lipid raft |
C0055546 | null | null | cholesterol-binding protein |
C0021868 | Thin structures that encapsulate subcellular structures or ORGANELLES in EUKARYOTIC CELLS. They include a variety of membranes associated with the CELL NUCLEUS; the MITOCHONDRIA; the GOLGI APPARATUS; the ENDOPLASMIC RETICULUM; LYSOSOMES; PLASTIDS; and VACUOLES. | Wall of organelle|Intracellular membrane|intracellular membrane|Membrane, Intracellular|Organelle wall|Membranes, Intracellular|Intracellular Membrane | Intracellular Membranes |
C0205132 | A mark that is long relative to its width; a length (straight or curved) without breadth or thickness; the trace of a moving point. | Linear|linings|linear|Line|line|lining|lined|Linear (qualifier value)|lines | Linear |
C0000968 | Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis. | Acetamides | Acetamides |
C0029432 | Mature osteoblasts that have become embedded in the BONE MATRIX. They occupy a small cavity, called lacuna, in the matrix and are connected to adjacent osteocytes via protoplasmic projections called canaliculi. | Bone cell|Osteocyte|Osteocytes|Osteocyte (cell)|osteocytes|osteocyte | Osteocytes |
C0055546 | null | null | cholesterol-binding protein |
C0597336 | Genetic loci associated with a QUANTITATIVE TRAIT. | Quantitative Trait Locus|Loci, Quantitative Trait|quantitative trait loci|quantitative trait loci (QTL)|quantitative trait locus|qtl|QTL|Trait Loci, Quantitative|Trait Locus, Quantitative|Locus, Quantitative Trait | Quantitative Trait Loci |
C0008656 | A specific pair of GROUP D CHROMOSOMES of the human chromosome classification. | Chromosome pair 14 (cell structure)|14 chromosome|chromosome 14|Chromosome pair 14|Chromosome 14 | Chromosomes, Human, Pair 14 |
C0002085 | Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. | Allele|ALLELE|Allelomorph|Genetic alleles (finding)|allele|Alleles|alleles|Allelomorphs|allelic gene|Genetic alleles | Alleles |
C0034987 | Nucleic acid sequences involved in regulating the expression of genes. | Nucleic acid regulatory sequence|Regulator Regions, Nucleic Acid|Nucleic Acid Regulatory Sequences|Regulatory Region|genetic regulatory element|Regions, Regulatory|Regulatory Regions, Nucleic Acid (Genetics)|Nucleic acid regulatory sequence (finding)|Regulatory Element|Regulatory Regions|Region, Regulatory | Regulatory Sequences, Nucleic Acid |
C0678341 | A duty, obligation, or burden; something for which one is responsible. | Responsibility|responsibilities|responsibility | Responsibility |
C0581602 | null | Structural modification (qualifier value)|Structural modification | Structural modification |
C0008060 | Abuse of children in a family, institutional, or other setting. (APA, Thesaurus of Psychological Index Terms, 1994) | Child maltreatment syndrome|child abuses|Child abuse (event)|Child Abuse|Child abuse, unspecified|Child Mistreatment|Mistreatment, Child|Abuse, Child|child abuse|Maltreatment, Child|Child abuse syndrome|CHILD ABUSE|Child Maltreatment|Child abuse | child abuse behavior |
C0038044 | Deliberate severe and repeated injury to one domestic partner by the other. | Spousal Abuse|Spouse Abuse|spousal abuse|Abuse, Spousal|Abuse, Spouse|abuse spouse|Battered spouse syndrome (finding)|Spousal abuse|Spouse abuse|battered spouse syndrome|Battered spouse syndrome|spouse abuse|abuse spousal | Spousal Abuse |
C0040480 | A motion or state where one end of a part is twisted about a longitudinal axis while the opposite end is held fast or turned in the opposite direction. | twist|Musculoskeletal torsion (observable entity)|torsions|torsion|twisting|Musculoskeletal torsion|Twisting|twists|Torsion|twisting body function | Musculoskeletal torsion, function |
C0745242 | null | immunoglobulin deficiency|Deficiency of immunoglobulin|Disorder of immunoglobulin|deficiencies immunoglobulin|Deficiency of immunoglobulin (disorder)|Immunoglobulin deficiency|Immunoglobulin deficiency (disorder) | Immunoglobulin deficiency |
C0272414 | A condition characterized by an abnormal spleen position due to loss, weakness, or malformation of one or more of the ligaments that hold the spleen in its normal position in the left upper abdomen. It may present as a birth defect or follow injuries or pregnancy. Signs and symptoms include abdominal discomfort and splenomegaly. | Wandering Spleens|Spleen, Drifting|Spleen, Wandering|Floating Spleens|wandering spleen|Wandering Spleen|Splenoptoses|Splenic Ptosis|Wandering spleen (disorder)|Ptosis, Splenic|Splenic Ptoses|Splenoptosis|Spleens, Floating|Drifting Spleen|Spleens, Displaced|Displaced Spleen|Wandering spleen|Lien migrans|Drifting Spleens|Lien mobilis|Spleen, Floating|Spleen, Displaced|Floating Spleen|Spleens, Drifting|Ptoses, Splenic|Displaced Spleens|Spleens, Wandering | Wandering Spleen |
C0026751 | null | Multiparous|Has had multiple live births|Multiparity|multiparity|multiparous|Multiparous (finding) | Multiparity |
C0031150 | A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY. If appropriate, biopsy or surgery can be performed during laparoscopy. | Laparoscopy|Coelioscopy|Laparoscopy, NOS|Laparoscopic procedure|Abdomen endoscopy|laparoscopic procedures|laparoscopy|Peritoneoscopies|Endoscopy of abdomen|Abdomen endoscopy (procedure)|laparoscopies|Laparoscopies|LAPAROSCOPY|diagnostic laparoscopy|celioscopy|laparoscopy procedure|laparoscopic procedure|Laparoscopic|Laparoscopy (GI only)|Laparoscopy (procedure)|peritoneoscopy|Celioscopies|Celioscopy|Peritoneoscopy|ABDOMEN: ENDOSCOPY | Laparoscopy |
C0162538 | A dysgammaglobulinemia characterized by a deficiency of IMMUNOGLOBULIN A. | Decreased immunoglobulin A|Deficiency, IgA|immunoglobulin a deficiency|Low levels of immunoglobulin A|Immunoglobulin A deficiency (disorder)|Gamma-A globulin deficiency|Decreased IgA|iga deficiency|Reduced IgA levels|Immunoglobulin A deficiency|IgA Deficiencies|deficiencies immunoglobulin|Deficiencies, IgA|IgA Deficiency|IgA deficiency|Decreased circulating IgA level|iga deficiencies|IGA DEFICIENCY, ISOLATED | Immunoglobulin A deficiency (disorder) |
C1305378 | null | Entire TA - Tendo achilles|Entire tendo achilles|Entire achilles tendon|Entire achilles tendon (body structure) | Entire achilles tendon |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.